Janux Therapeutics, Inc.

As of September 26, 2025, Janux Therapeutics, Inc. has shifted to a mildly bearish trend, with mixed indicators showing mild bullishness on the weekly MACD but bearishness on the monthly MACD, while significantly underperforming the S&P 500 over the past month and year.

As of September 26, 2025, Janux Therapeutics, Inc. shows a mildly bearish trend, with mixed MACD signals and underperformance compared to the S&P 500, recording a year-to-date return of -56.61% against the S&P's 12.96%.

As of May 19, 2025, Janux Therapeutics, Inc. shows a mildly bearish technical trend, with mixed signals across different time frames, underperforming the S&P 500 significantly year-to-date and over the past year.

As of August 7, 2025, Janux Therapeutics, Inc. is considered overvalued and has deteriorated to a "does not qualify" valuation grade, with negative earnings metrics and a year-to-date return of -54.43%, significantly underperforming compared to the S&P 500's 12.22% return.

As of November 9, 2021, Janux Therapeutics, Inc. is considered "risky" and overvalued with key financial metrics indicating underperformance compared to peers, including a year-to-date return of -57.27% versus the S&P 500's 2.44%.

As of March 21, 2024, Janux Therapeutics, Inc. shows a moderate bullish trend overall, despite mixed signals from various indicators, with weekly MACD mildly bullish and daily moving averages indicating short-term weakness.

Janux Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $24 million and a market cap of approximately $1.37 billion. The company has no dividend yield and negative return on equity.

As of Jun 18, Janux Therapeutics, Inc. has a market capitalization of 1,365.77 million, with net sales of 9.34 million and a net profit of -77.75 million over the latest four quarters. The company reported shareholder's funds of 1,022.78 million and total assets of 1,061.52 million as of Dec 24.